Brenipatide

Brenipatide
Clinical data
Other namesLY-3537031; LY3537031
Routes of
administration		Subcutaneous injection[1][2]
Drug classGLP-1 receptor agonist; GIP receptor agonist
Identifiers
  • D-Tyrosyl-2-methylalanyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-tyrosyl-L-seryl-L-isoleucyl-2-methyl-L-leucyl-L-leucyl-L-α-aspartyl-L-lysyl-N6-[N-(19-carboxy-1-oxononadecyl) -L-γ-glutamyl-2-[2-(2-aminoethoxy)ethoxy]acetyl-2-[2-(2-aminoethoxy)ethoxy]acetyl] -L-lysyl-L-alanyl-L-glutaminyl-2-methylalanyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-α-glutamyl-α-methyl-L-tyrosyl-L-leucyl-L-isoleucyl-L-alanylglycylglycyl-L-prolyl-L-seryl-L-serylglycyl-L-alanyl-L-prolyl-L-prolyl-L-prolyl-L-serinamide
CAS Number
PubChem SID
UNII
Chemical and physical data
FormulaC228H354N46O72
Molar mass4891.590 g·mol−1

Brenipatide (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name LY-3537031) is a dual glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptor agonist which is under development for the treatment of alcoholism, bipolar disorder, asthma, smoking withdrawal, cardiovascular disorders, liver disorders, metabolic disorders, and obesity.[1][2] It is taken by subcutaneous injection once per month.[1][2] The drug has a longer elimination half-life than tirzepatide or retatrutide.[2] Brenipatide is under development by Eli Lilly and Company.[1] As of December 2025, it is in phase 3 clinical trials for alcoholism and bipolar disorder, phase 2 trials for asthma and smoking withdrawal, and phase 1 trials for cardiovascular disorders, liver disorders, metabolic disorders, and obesity.[1]

See also

References

  1. ^ a b c d e "Brenipatide - Eli Lily and Company". AdisInsight. 22 December 2025. Retrieved 13 January 2026.
  2. ^ a b c d Østergaard S (December 2025). "Advancing obesity treatments through innovations in the design and manufacturing of therapeutic peptides". Expert Opinion on Drug Discovery: 1–24. doi:10.1080/17460441.2025.2601113. PMID 41381216. Brenipatide is a once-monthly dual-acting peptide from Eli Lilly that targets GLP-1R and GIPR (Table 1) and is currently in a Phase 3 clinical trial for moderate-to-severe alcohol use disorder (NCT07219966). Although it has a single C20 diacid, it exhibits a longer half-life than tirzepatide and retatrutide, likely because of a backbone optimized for stability against enzymatic degradation through a Trp to αMe-Tyr substitution.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.